{
  "main_header": {
    "sid": 302214,
    "name": "Beryl Drugs",
    "stock_name": "Beryl Drugs",
    "full_name": "Beryl Drugs Ltd",
    "name_url": "stocks-analysis/beryl-drugs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "23.20",
    "chg": -0.79,
    "chgp": "-3.29%",
    "dir": -1,
    "prev_price": "23.99",
    "mcapval": "12.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524606,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE415H01017",
    "curr_date": "Dec 24",
    "curr_time": "",
    "bse_nse_vol": "1.25 k",
    "exc_status": "Active",
    "traded_date": "Dec 24, 2025",
    "traded_date_str": "2025 12 24",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/beryl-drugs-302214-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Beryl Drugs Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-beryl-drugs-ltd-fallingrising-3767506",
        "imagepath": "",
        "date": "2025-12-24 02:10:18",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Short-Term Performance Outshines Benchmark</strong></p>\n<p>In the week leading up to 23-Dec, Beryl Drugs Ltd's stock surged by 9.14%, significantly outpacing the Sensex's modest 1.00% gain over the same period. This strong weekly performance is complemented by a one-month return of 5.45%, again outperforming the Sensex's 0.34% rise. Despite these short-term gains, the stock remains under pressure on a year-to-date basis, with a decline of 33.64%, contrasting with the Sensex's 9.45% appreciation. Over the longer term, however, Beryl Drugs has delivered impressive returns, with a three-year gain of 105.04% and a five-year surge of 238.84%, both well above the Sensex's respective 42.91% and 84.15% increases.</p>\n<p><strong>Technical Indicators Signal Strength</strong></p>\n<p>The stock's current..."
      },
      {
        "title": "Beryl Drugs Sees Revision in Market Evaluation Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/beryl-drugs-upgraded-from-strong-sell-to-sell-by-marketsmojo-on-2-sep-2025-3755068",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BerylDrugs_mojoScore_3755068.png",
        "date": "2025-12-10 10:10:40",
        "description": "Beryl Drugs, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key analytical parameters. This adjustment comes amid a backdrop of mixed financial performance and market returns, offering investors a fresh perspective on the stock’s current standing."
      },
      {
        "title": "Why is Beryl Drugs falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-beryl-drugs-fallingrising-3716008",
        "imagepath": "",
        "date": "2025-11-19 21:56:55",
        "description": "As of 19-Nov, Beryl Drugs Ltd is experiencing a decline in its stock price, currently at Rs 22.25, which represents a decrease of Rs 1.12 or 4.79%. The stock has been underperforming, having lost 7.64% over the last four days, and it is trading below all key moving averages, indicating a bearish trend. Additionally, the stock's delivery volume has significantly decreased by 94.66% compared to the 5-day average, suggesting a lack of investor interest. The stock has also shown poor performance over various time frames, with a year-to-date decline of 38.45%, further contributing to the negative sentiment surrounding it.\n\nIn the broader market context, Beryl Drugs' recent performance contrasts sharply with the Sensex, which has gained 0.85% over the past week and 9.02% year-to-date. This underperformance highlights the stock's struggles relative to the overall market, as it has consistently lagged behind the be..."
      },
      {
        "title": "Beryl Drugs Q2 FY26: Marginal Profit Recovery Amid Revenue Decline and Persistent Margin Pressures",
        "link": "https://www.marketsmojo.com/news/result-analysis/beryl-drugs-q2-fy26-marginal-profit-recovery-amid-revenue-decline-and-persistent-margin-pressures-3715858",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/BerylDrugs_quaterlyResult_3715858.png",
        "date": "2025-11-15 09:24:09",
        "description": "Beryl Drugs Limited, the Indore-based pharmaceutical formulations manufacturer, reported a marginal improvement in profitability for Q2 FY26, posting net profit of ₹0.01 crores compared to ₹0.02 crores in the previous quarter, though this represented a sharp decline from ₹0.01 crores in the year-ago period. With a micro-cap market capitalisation of just ₹12.00 crores and shares trading at ₹23.95, the company continues to grapple with fundamental challenges that have kept institutional investors at bay and prompted a cautious stance from analysts."
      },
      {
        "title": "How has been the historical performance of Beryl Drugs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-beryl-drugs-3698943",
        "imagepath": "",
        "date": "2025-11-13 23:17:13",
        "description": "Answer:\nThe historical performance of Beryl Drugs shows a fluctuating trend in key financial metrics over the years.\n\nBreakdown:\nBeryl Drugs' net sales peaked at 26.89 Cr in Mar'23 but declined to 21.15 Cr by Mar'25. Other operating income increased from 0.00 Cr in Mar'19 to 1.41 Cr in Mar'25, contributing to a total operating income that reached a high of 27.16 Cr in Mar'23 before falling to 22.56 Cr in Mar'25. The raw material cost also saw a decline from 14.23 Cr in Mar'23 to 11.12 Cr in Mar'25, while total expenditure decreased from 24.95 Cr in Mar'23 to 19.91 Cr in Mar'25. Operating profit (PBDIT) slightly decreased from 2.68 Cr in Mar'24 to 2.65 Cr in Mar'25, with profit before tax showing a decline from 1.01 Cr in Mar'24 to 0.87 Cr in Mar'25. Profit after tax also decreased from 0.77 Cr in Mar'24 to 0.58 Cr in Mar'25. The company's total assets decreased from 17.39 Cr in Mar'23 to 15.95 Cr in Mar'25,..."
      },
      {
        "title": "Why is Beryl Drugs falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-beryl-drugs-fallingrising-3656483",
        "imagepath": "",
        "date": "2025-10-29 21:39:34",
        "description": "As of 29-Oct, Beryl Drugs Ltd's stock price is currently at Rs 24.00, reflecting an increase of Rs 1.0 or 4.35%. The stock has been gaining for the last two days, with a total return of 4.39% during this period. It has outperformed its sector by 3.61% today and reached an intraday high of Rs 27.6, which is a 20% increase. However, despite these positive movements, the stock has shown a significant year-to-date decline of 33.61% and a one-year decline of 35.12%. Additionally, there has been a notable drop in investor participation, with delivery volume falling by 69.25% against the five-day average, indicating a potential concern regarding sustained interest in the stock.\n\nBroader Market Context: In the short term, Beryl Drugs has outperformed the Sensex, with a one-week return of 7.62% compared to the benchmark's 0.68%. This indicates that while the stock is experiencing a positive momentum recently, it has..."
      },
      {
        "title": "Why is Beryl Drugs falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-beryl-drugs-fallingrising-3600411",
        "imagepath": "",
        "date": "2025-10-07 21:36:34",
        "description": "As of 07-Oct, Beryl Drugs Ltd is experiencing a decline in its stock price, currently at Rs 22.75, which reflects a decrease of Rs 1.24 or 5.17%. Today's price summary indicates that the stock has underperformed its sector by 5.48%, and it has fallen after three consecutive days of gains. The stock touched an intraday low of Rs 22, marking an 8.3% drop. Additionally, the delivery volume has decreased significantly, falling by 46.41% against the five-day average, suggesting a decline in investor participation. Over the longer term, the stock has seen a year-to-date decline of 37.07% and a one-year decline of 41.77%, indicating ongoing challenges.\n\nIn the broader market context, Beryl Drugs' short-term performance over the past week shows a gain of 2.29%, which slightly outpaces the Sensex's increase of 2.07%. However, the stock's longer-term performance contrasts sharply with the benchmark, as it has underpe..."
      },
      {
        "title": "Why is Beryl Drugs falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-beryl-drugs-fallingrising-3595936",
        "imagepath": "",
        "date": "2025-10-06 21:27:11",
        "description": "As of 06-Oct, Beryl Drugs Ltd is experiencing a price increase, currently at 23.99, with a change of 0.54, representing a 2.3% rise. The stock has shown strong performance recently, gaining 7.87% over the last two days and outperforming its sector by 2.19%. In terms of longer-term performance, the stock has increased by 7.82% over the past week, although it has seen a slight decline of 0.08% over the past month. Notably, the stock's delivery volume has surged by 287.03% against the five-day average, indicating rising investor participation. However, there is no information available regarding positive or negative factors that could influence the stock's movement.\n\nIn the broader market context, Beryl Drugs' recent short-term return of 7.82% over the past week significantly outpaces the Sensex, which has only increased by 1.77% in the same period. This suggests that the stock is gaining traction relative to ..."
      },
      {
        "title": "Why is Beryl Drugs falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-beryl-drugs-fallingrising-3574998",
        "imagepath": "",
        "date": "2025-09-26 21:20:29",
        "description": "As of 26-Sep, Beryl Drugs Ltd is experiencing a decline in its stock price, currently at Rs 22.39, which reflects a decrease of Rs 1.36 or 5.73%. The stock has underperformed its sector by 3.39% today and has been on a consecutive downward trend for the last two days, accumulating a total loss of 7.44% during this period. The stock reached an intraday low of Rs 21.5, marking a significant drop of 9.47%. Over the past week, Beryl Drugs has seen a return of -1.97%, and over the past month, it has declined by 12.20%. Year-to-date, the stock has fallen by 38.06%, contrasting sharply with the Sensex, which has gained 2.93% during the same timeframe. Notably, the stock's delivery volume has plummeted by 93.96% against its five-day average, indicating a significant drop in investor participation.\n\nIn the broader market context, the pharmaceuticals and drugs sector has also faced challenges, with a decline of 2.35%..."
      }
    ],
    "total": 270,
    "sid": "302214",
    "stock_news_url": "https://www.marketsmojo.com/news/beryl-drugs-302214"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "15-Nov-2025",
      "details": "results publication for quarter/ half year ended 30.09.2025",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for OUTCOME OF BOARD MEETING",
      "datetime": "13-Nov-2025",
      "details": "OUTCOME OF BOARD MEETING",
      "source": "BSE"
    },
    {
      "caption": "UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER 2025",
      "datetime": "13-Nov-2025",
      "details": "UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Beryl Drugs Ltd falling/rising?

2025-12-24 02:10:18

Short-Term Performance Outshines Benchmark

In the week leading up to 23-Dec, Beryl Drugs Ltd's stock surged by 9.14%, significantly outpacing the Sensex's modest 1.00% gain over the same period. This strong weekly performance is complemented by a one-month return of 5.45%, again outperforming the Sensex's 0.34% rise. Despite these short-term gains, the stock remains under pressure on a year-to-date basis, with a decline of 33.64%, contrasting with the Sensex's 9.45% appreciation. Over the longer term, however, Beryl Drugs has delivered impressive returns, with a three-year gain of 105.04% and a five-year surge of 238.84%, both well above the Sensex's respective 42.91% and 84.15% increases.

Technical Indicators Signal Strength

The stock's current...

Read More

Beryl Drugs Sees Revision in Market Evaluation Amid Mixed Financial Signals

2025-12-10 10:10:40

Beryl Drugs, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key analytical parameters. This adjustment comes amid a backdrop of mixed financial performance and market returns, offering investors a fresh perspective on the stock’s current standing.

Read More

Why is Beryl Drugs falling/rising?

2025-11-19 21:56:55

As of 19-Nov, Beryl Drugs Ltd is experiencing a decline in its stock price, currently at Rs 22.25, which represents a decrease of Rs 1.12 or 4.79%. The stock has been underperforming, having lost 7.64% over the last four days, and it is trading below all key moving averages, indicating a bearish trend. Additionally, the stock's delivery volume has significantly decreased by 94.66% compared to the 5-day average, suggesting a lack of investor interest. The stock has also shown poor performance over various time frames, with a year-to-date decline of 38.45%, further contributing to the negative sentiment surrounding it. In the broader market context, Beryl Drugs' recent performance contrasts sharply with the Sensex, which has gained 0.85% over the past week and 9.02% year-to-date. This underperformance highlights the stock's struggles relative to the overall market, as it has consistently lagged behind the be...

Read More

Beryl Drugs Q2 FY26: Marginal Profit Recovery Amid Revenue Decline and Persistent Margin Pressures

2025-11-15 09:24:09

Beryl Drugs Limited, the Indore-based pharmaceutical formulations manufacturer, reported a marginal improvement in profitability for Q2 FY26, posting net profit of ₹0.01 crores compared to ₹0.02 crores in the previous quarter, though this represented a sharp decline from ₹0.01 crores in the year-ago period. With a micro-cap market capitalisation of just ₹12.00 crores and shares trading at ₹23.95, the company continues to grapple with fundamental challenges that have kept institutional investors at bay and prompted a cautious stance from analysts.

Read More

How has been the historical performance of Beryl Drugs?

2025-11-13 23:17:13

Answer: The historical performance of Beryl Drugs shows a fluctuating trend in key financial metrics over the years. Breakdown: Beryl Drugs' net sales peaked at 26.89 Cr in Mar'23 but declined to 21.15 Cr by Mar'25. Other operating income increased from 0.00 Cr in Mar'19 to 1.41 Cr in Mar'25, contributing to a total operating income that reached a high of 27.16 Cr in Mar'23 before falling to 22.56 Cr in Mar'25. The raw material cost also saw a decline from 14.23 Cr in Mar'23 to 11.12 Cr in Mar'25, while total expenditure decreased from 24.95 Cr in Mar'23 to 19.91 Cr in Mar'25. Operating profit (PBDIT) slightly decreased from 2.68 Cr in Mar'24 to 2.65 Cr in Mar'25, with profit before tax showing a decline from 1.01 Cr in Mar'24 to 0.87 Cr in Mar'25. Profit after tax also decreased from 0.77 Cr in Mar'24 to 0.58 Cr in Mar'25. The company's total assets decreased from 17.39 Cr in Mar'23 to 15.95 Cr in Mar'25,...

Read More

Why is Beryl Drugs falling/rising?

2025-10-29 21:39:34

As of 29-Oct, Beryl Drugs Ltd's stock price is currently at Rs 24.00, reflecting an increase of Rs 1.0 or 4.35%. The stock has been gaining for the last two days, with a total return of 4.39% during this period. It has outperformed its sector by 3.61% today and reached an intraday high of Rs 27.6, which is a 20% increase. However, despite these positive movements, the stock has shown a significant year-to-date decline of 33.61% and a one-year decline of 35.12%. Additionally, there has been a notable drop in investor participation, with delivery volume falling by 69.25% against the five-day average, indicating a potential concern regarding sustained interest in the stock. Broader Market Context: In the short term, Beryl Drugs has outperformed the Sensex, with a one-week return of 7.62% compared to the benchmark's 0.68%. This indicates that while the stock is experiencing a positive momentum recently, it has...

Read More

Why is Beryl Drugs falling/rising?

2025-10-07 21:36:34

As of 07-Oct, Beryl Drugs Ltd is experiencing a decline in its stock price, currently at Rs 22.75, which reflects a decrease of Rs 1.24 or 5.17%. Today's price summary indicates that the stock has underperformed its sector by 5.48%, and it has fallen after three consecutive days of gains. The stock touched an intraday low of Rs 22, marking an 8.3% drop. Additionally, the delivery volume has decreased significantly, falling by 46.41% against the five-day average, suggesting a decline in investor participation. Over the longer term, the stock has seen a year-to-date decline of 37.07% and a one-year decline of 41.77%, indicating ongoing challenges. In the broader market context, Beryl Drugs' short-term performance over the past week shows a gain of 2.29%, which slightly outpaces the Sensex's increase of 2.07%. However, the stock's longer-term performance contrasts sharply with the benchmark, as it has underpe...

Read More

Why is Beryl Drugs falling/rising?

2025-10-06 21:27:11

As of 06-Oct, Beryl Drugs Ltd is experiencing a price increase, currently at 23.99, with a change of 0.54, representing a 2.3% rise. The stock has shown strong performance recently, gaining 7.87% over the last two days and outperforming its sector by 2.19%. In terms of longer-term performance, the stock has increased by 7.82% over the past week, although it has seen a slight decline of 0.08% over the past month. Notably, the stock's delivery volume has surged by 287.03% against the five-day average, indicating rising investor participation. However, there is no information available regarding positive or negative factors that could influence the stock's movement. In the broader market context, Beryl Drugs' recent short-term return of 7.82% over the past week significantly outpaces the Sensex, which has only increased by 1.77% in the same period. This suggests that the stock is gaining traction relative to ...

Read More

Why is Beryl Drugs falling/rising?

2025-09-26 21:20:29

As of 26-Sep, Beryl Drugs Ltd is experiencing a decline in its stock price, currently at Rs 22.39, which reflects a decrease of Rs 1.36 or 5.73%. The stock has underperformed its sector by 3.39% today and has been on a consecutive downward trend for the last two days, accumulating a total loss of 7.44% during this period. The stock reached an intraday low of Rs 21.5, marking a significant drop of 9.47%. Over the past week, Beryl Drugs has seen a return of -1.97%, and over the past month, it has declined by 12.20%. Year-to-date, the stock has fallen by 38.06%, contrasting sharply with the Sensex, which has gained 2.93% during the same timeframe. Notably, the stock's delivery volume has plummeted by 93.96% against its five-day average, indicating a significant drop in investor participation. In the broader market context, the pharmaceuticals and drugs sector has also faced challenges, with a decline of 2.35%...

Read More

View All News